5 Horizons Capital

Investment thesis

5 Horizons Capital focuses on supporting clinical-stage biotechnology companies through a unique Venture Capital-as-a-Service (VCaaS) model that integrates capital, advisory services, and partnerships with CROs to accelerate clinical progress.

Focus narrative

The primary focus of 5 Horizons Capital is on early-stage clinical biotechnology companies, particularly those in the Series A stage. The organization emphasizes thorough diligence across scientific, clinical, operational, and financial aspects, ensuring that investments are strategically aligned with CRO milestones and trial progression. Their approach is designed to enhance capital efficiency and foster strong partnerships within the biotech ecosystem.

Value beyond capital

5 Horizons Capital adds value to its portfolio companies by integrating capital with operational execution through strategic partnerships with CROs like Novotech. This unique approach not only provides financial support but also enhances the operational capabilities of clinical-stage biotechs, helping them navigate the complexities of clinical trials more effectively.

Community overview

5 Horizons Capital is a venture capital organization founded to support clinical-stage biotechs. It operates as a Venture Capital-as-a-Service (VCaaS) platform, integrating capital, advisory services, and partnerships with Contract Research Organizations (CROs) to facilitate clinical progress for biotech companies.

Community focus

The organization invests in clinical-stage biotechnology companies, providing comprehensive diligence across scientific, clinical, operational, and financial aspects. They emphasize capital efficiency and aligned incentives among stakeholders to accelerate the path from discovery to clinical trials.